Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>On December 12, 2025, shares of Ascendis Pharma A/S spiked 8% in intraday trading, fueled by sudden market chatter suggesting the Danish rare disease biotech may be in the crosshairs of a potential acquirer.</li><li>With no confirmed bidder or public announcement to validate the speculation, investors and analysts were left parsing through the noise, weighing the potential strategic rationale for a deal.</li><li>At a market capitalization of $11.8 billion, Ascendis stands out with a growing commercial footprint anchored by its approved products SKYTROFA and YORVIPATH, a robust pipeline including TransCon CNP, and a long-term vision aimed at €5 billion in annual revenue by 2030.</li></ul>

On December 12, 2025, shares of Ascendis Pharma A/S spiked 8% in intraday trading, fueled by sudden market chatter suggesting the Danish rare disease biotech may be in the crosshairs of a potential acquirer.With no confirmed bidder or public announcement to validate the speculation, investors and analysts were left parsing through the noise, weighing the potential strategic rationale for a deal.At a market capitalization of $11.8 billion, Ascendis stands out with a growing commercial footprint anchored by its approved products SKYTROFA and YORVIPATH, a robust pipeline including TransCon CNP, and a long-term vision aimed at €5 billion in annual revenue by 2030.

Ascendis Pharma Just Popped 8%—Is a Multi-Billion-Dollar Acquisition Brewing?